MUMBAI: AstraZeneca Pharma India today said it has received marketing authorisation from the Drug Controller General of India (DCGI) for Symbicort, a medicine used for treatment of asthma "We have received marketing authorisation from the Drug Controller General of India (DCGI) for Symbicort 320 mcg. It is a fixed-dose combination drug comprising budesonide and formoterol fumarate dehydrate delivered through a special device. "Asthma and COPD are common and major causes of chronic morbidity impacting millions of patients in India. Symbicort will offer physicians and patients another treatment option for severe asthma and for moderate to severe COPD," said Anilda D'souza, a senior executive of AstraZeneca India.Asthma is a common and chronic condition that affects the lungs' airways. Inflammation and narrowing of the airways may cause wheezing, breathlessness, chest tightness and coughing.

Source: Economic Times June 20, 2017 13:41 UTC